Comparative oncology: overcoming human cancer through companion animal studies

참고문헌 (123)

1. Pruitt, K., "Molecular and cellular changes during cancer progression resulting from genetic and epigenetic alterations", Prog. Mol. Biol. Transl. Sci, 144, pp.3~47 (2016)
2. Hanahan, D., "Hallmarks of cancer : new dimensions", Cancer Discov, 12, pp.31~46 (2022)
3. Schreiber, R. D., "Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
4. Seyfried, T. N., "Cancer as a metabolic disease: implications for novel therapeutics", Carcinogenesis, 35, pp.515~527 (2014)
5. Neophytou, C. M., "The role of tumor microenvironment in cancer metastasis : molecular mechanisms and therapeutic opportunities", Cancers, 13, pp.2053~ (2021)
6. Dancey, J. E., "The genetic basis for cancer treatment decisions", Cell, 148, pp.409~420 (2012)
7. Olivier, M., "TP53 mutations in human cancers : origins, consequences, and clinical use", Cold Spring Harb. Perspect. Biol, 2, pp.a001008~ (2010)
8. Wishart, D. S., "Is cancer a genetic disease or a metabolic disease?", EBioMedicine, 2, pp.478~479 (2015)
9. Harris, H., "Mitosis in hybrid cells derived from mouse and man", Nature, 207, pp.606~608 (1965)
10. Harris, H., "Hybrid cells derived from mouse and man: artificial heterokaryons of mammalian cells from different species", Nature, 205, pp.640~646 (1965)
11. Seyfried, T. N., "Cancer as a metabolic disease", Nutr. Metab, 7, pp.7~ (2010)
12. Seyfried, T. N., "Cancer as a mitochondrial metabolic disease", Front. Cell Dev. Biol, 3, pp.43~ (2015)
13. Shurin, M. R., "Intratumoral cytokines", chemokines, Cancer Metastasis Rev, pp.2006, 25[DOI]
14. Chakraborty, S., "The difficulties in cancer treatment", Ecancermedicalscience, 6, pp.ed16~ (2012)
15. Schiffman, J. D., "Comparative oncology : what dogs and other species can teach us about humans with cancer", Philos. Trans. R. Soc. Lond. B Biol. Sci, 370, pp.20140231~ (2015)
16. Dhawan, D., "Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer", PLoS Genet, 14, pp.e1007571~ (2018)
17. Hernandez, B., "Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas", Int. J. Mol. Sci, 19, pp.394~ (2018)
18. Onaciu, A., "Spontaneous and induced animal models for cancer research", Diagnostics, 10, pp.660~ (2020)
19. Davis, B. W., "Domestic dogs and cancer research : a breedbased genomics approach", ILAR J, 55, pp.59~68 (2014)
20. Paoloni, M., "Translation of new cancer treatments from pet dogs to humans", Nat. Rev. Cancer, 8, pp.147~156 (2008)
21. "Integrative mapping of the dog epigenome: reference annotation for comparative inter-tissue and cross-species studies" (2022)[URL]
22. Feng, Y., "Breast cancer development and progression : risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis", Genes Dis, 5, pp.77~106 (2018)
23. McCart Reed, A. E., "Mixed ductal-lobular carcinomas : evidence for progression from ductal to lobular morphology", J. Pathol, 244, pp.460~468 (2018)
24. Lukasiewicz, S., "Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review", Cancers, 13, pp.4287~ (2021)
25. Waks, A. G., "Breast cancer treatment: a review", JAMA, 321, pp.288~300 (2019)
26. Sultan, F., "Comparative oncology : integrating human and veterinary medicine", Open Vet. J, 8, pp.25~34 (2018)
27. Hansen, K., "Spontaneous and genetically engineered animal models; use in preclinical cancer drug development", Eur. J. Cancer, 40, pp.858~880 (2004)
28. Sorenmo, K. U., "Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence", Vet. Comp. Oncol, 7, pp.162~172 (2009)
29. Varallo, G. R., "Prognostic phenotypic classification for canine mammary tumors", Oncol. Lett, 18, pp.6545~6553 (2019)
30. Kim, T. M., "Cross-species oncogenic signatures of breast cancer in canine mammary tumors", Nat. Commun, 11, pp.3616~ (2020)
31. Lee, K. H., "Somatic mutation of PIK3CA (H1047R) is a common driver mutation hotspot in canine mammary tumors as well as human breast cancers", Cancers, 11, pp.2006~ (2019)
32. Lorch, G., "Identification of recurrent activating HER2 mutations in primary canine pulmonary adenocarcinoma", Clin. Cancer Res, 25, pp.5866~5877 (2019)
33. Seung, B. J., "Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors : comparison with immunohistochemistry analysis", PLoS ONE, 15, pp.e0229031~ (2020)
34. Nam, A. R., "Alternative methylation of intron motifs is associated with cancer-related gene expression in both canine mammary tumor and human breast cancer", Clin. Epigenetics, 12, pp.110~ (2020)
35. Jeong, S. J., "Genome-wide methylation profiling in canine mammary tumor reveals miRNA candidates associated with human breast cancer", Cancers, 11, pp.1466~ (2019)
36. Lee, K. H, "Methylation of LINE-1 in cell-free DNA serves as a liquid biopsy biomarker for human breast cancers and dog mammary tumors", Sci. Rep, 9, pp.175~ (2019)
37. Lee, K. H., "Transcriptome signatures of canine mammary gland tumors and its comparison to human breast cancers", Cancers, 10, pp.317~ (2018)
38. Hyoung-Min Park, "Common plasma protein marker LCAT in aggressive human breast cancer and canine mammary tumor", BMB Reports, 53(12), pp.664~669 (2020), 생화학분자생물학회[DOI]
39. Rawla, P., "Epidemiology of prostate cancer", World J. Oncol, 10, pp.63~89 (2019)
40. Laufer-Amorim, R., "Comprehensive genomic profiling of androgenreceptor-negative canine prostate cancer", Int. J. Mol. Sci, 20, pp.1555~ (2019)
41. Christensen, B. W., "Canine prostate disease", Vet. Clin. North Am. Small Anim. Pract, 48, pp.701~719 (2018)
42. Leroy, B. E., "Prostate cancer in dogs : comparative and clinical aspects", Vet. J, 180, pp.149~162 (2009)
43. Iizuka, K., "Comparison of outcomes between medical and surgical treatment in dogs with prostatic adenocarcinoma : a retrospective study", BMC Vet. Res, 18, pp.36~ (2022)
44. Baek, S. J., "Review paper : Cancer chemopreventive compounds and canine cancer", Vet. Pathol, 46, pp.576~588 (2009)
45. Ryman-Tubb, T., "Comparative pathology of dog and human prostate cancer", Vet. Med. Sci, 8, pp.110~120 (2022)
46. Davey, R. A., "Androgen receptor structure, function and biology : from bench to bedside", Clin. Biochem. Rev, 37, pp.3~15 (2016)
47. Takayama, K., "Transcriptional network of androgen receptor in prostate cancer progression", Int. J. Urol, 20, pp.756~768 (2013)
48. Kazutoshi Fujita, "Role of Androgen Receptor in Prostate Cancer: A Review", The World Journal of Men's Health, 37(3), pp.288~295 (2019), 대한남성과학회[DOI]
49. Formaggio, N., "Loss and revival of androgen receptor signaling in advanced prostate cancer", Oncogene, 40, pp.1205~1216 (2021)
50. Robinson, D., "Integrative clinical genomics of advanced prostate cancer", Cell, 162, pp.454~ (2015)
51. Leung, J. K., "Non-genomic actions of the androgen receptor in prostate cancer", Front. Endocrinol, 8, pp.2~ (2017)
52. Lin, H. Y., "Is STAT3 and PTEN expression altered in canine prostate cancer? J", Comp. Pathol, 155, pp.185~189 (2016)
53. Leis-Filho, A. F., "Expression and prognostic significance of vascular endothelial growth factor-A(VEGF-A)and its receptor in canine prostate cancer", Prostate, 81, pp.1021~1031 (2021)
54. Nicholson, A. G., "The 2021 WHO Classification of lung tumors : impact of advances since 2015", J. Thorac. Oncol, 17, pp.362~387 (2022)
55. Raso, M. G., "Pathology and classification of SCLC", Cancers, 13, pp.820~ (2021)
56. Hifumi, T., "Immunohistochemical detection of proteins associated with multidrug resistance to anticancer drugs in canine and feline primary pulmonary carcinoma", J. Vet. Med. Sci, 72, pp.665~668 (2010)
57. Lee, B. M., "Retrospective evaluation of a modified human lung cancer stage classification in dogs with surgically excised primary pulmonary carcinomas", Vet. Comp. Oncol, 18, pp.590~598 (2020)
58. Hellmann, M. D., "Nivolumab plus ipilimumab in advanced non-small-cell lung cancer", N. Engl. J. Med, 381, pp.2020~2031 (2019)
59. Dafni, U., "Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced nonsmall cell lung cancer. A systematic review and network meta-analysis", Lung Cancer, 134, pp.127~140 (2019)
60. D’Arcangelo, M., "Rare mutations in non-small-cell lung cancer", Future Oncol, 9, pp.699~711 (2013)
61. Govindan, R., "Genomic landscape of non-small cell lung cancer in smokers and never-smokers", Cell, 150, pp.1121~1134 (2012)
62. Higuchi, T., "Characterization and treatment of transitional cell carcinoma of the abdominal wall in dogs : 24 cases(1985-2010)", J. Am. Vet. Med. Assoc, 242, pp.499~506 (2013)
63. Park, J. C., "Bladder cancer : a disease ripe for major advances", Clin. Adv. Hematol. Oncol, 12, pp.838~845 (2014)
64. Zhu, S., "Traditional classification and novel subtyping systems for bladder cancer", Front. Oncol, 10, pp.102~ (2020)
65. Kobayashi, T., "Understanding the biology of urothelial cancer metastasis", Asian J. Urol, 3, pp.211~222 (2016)
66. Ramsey, S. A., "Cross-species analysis of the canine and human bladder cancer transcriptome and exome", Genes Chromosomes Cancer, 56, pp.328~343 (2017)
67. de Brot, S., "The dog as an animal model for bladder and urethral urothelial carcinoma : comparative epidemiology and histology", Oncol. Lett, 16, pp.1641~1649 (2018)
68. Knapp, D. W., "Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development", ILAR J, 55, pp.100~118 (2014)
69. Shapiro, S. G., "Canine urothelial carcinoma : genomically aberrant and comparatively relevant", Chromosome Res, 23, pp.311~331 (2015)
70. Decker, B., "Homologous mutation to human BRAF V600E is common in naturally occurring canine bladder cancer-evidence for a relevant model system and urine-based diagnostic test", Mol. Cancer Res, 13, pp.993~1002 (2015)
71. Mochizuki, H., "Comparative aspects of BRAF mutations in canine cancers", Vet. Sci, 2, pp.231~245 (2015)
72. Mochizuki, H., "BRAF mutations in canine cancers", PLoS ONE, 10, pp.e0129534~ (2015)
73. Omuro, A., "Glioblastoma and other malignant gliomas: a clinical review", JAMA, 310, pp.1842~1850 (2013)
74. Jose-Lopez, R., "Clinical features, diagnosis, and survival analysis of dogs with glioma", J. Vet. Intern. Med, 35, pp.1902~1917 (2021)
75. Merickel, J. L., "Prognostic histopathologic features of canine glial tumors", Vet. Pathol, 58, pp.945~951 (2021)
76. Pluhar, G. E., "Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy", Vaccine, 28, pp.3371~3378 (2010)
77. Boudreau, C. E., "Intratumoral delivery of STING agonist results in clinical responses in canine glioblastoma", Clin. Cancer Res, 27, pp.5528~5535 (2021)
78. Miller, A. D., "Canine primary intracranial cancer : a clinicopathologic and comparative review of glioma, meningioma, and choroid plexus tumors", Front. Oncol, 9, pp.1151~ (2019)
79. Hidalgo Crespo, E., "Survival time after surgical debulking and temozolomide adjuvant chemotherapy in canine intracranial gliomas", Vet. Sci, 9, pp.427~ (2022)
80. Lai, W., "Integrated analysis of single-cell RNAseq dataset and bulk RNA-seq dataset constructs a prognostic model for predicting survival in human glioblastoma", Brain Behav, 12, pp.e2575~ (2022)
81. Rajaraman, P., "Genome-wide association study of glioma and metaanalysis", Hum. Genet, 131, pp.1877~1888 (2012)
82. Couturier, C. P., "Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy", Nat. Commun, 11, pp.3406~ (2020)
83. Han, S., "Alterations in the RTK", Ras, AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas, pp.Aging, 2021[DOI]
84. Dickinson, P. J., "Chromosomal aberrations in canine gliomas define candidate genes and common pathways in dogs and humans", J. Neuropathol. Exp. Neurol, 75, pp.700~710 (2016)
85. Colardo, M., "Targeting RTK-PI3K-mTOR axis in gliomas : an update", Int. J. Mol. Sci, 22, pp.4899~ (2021)
86. Kramar, F., "IDH1", 2 mutation and MGMT promoter methylation—the relevant survival predictors in Czech patients with brain gliomas, 2016, pp.62, 194~202
87. Mizoguchi, M., "Molecular characteristics of glioblastoma with 1p", 19q codeletion, 2012, pp.29, 148~153
88. Sample, A., "Mechanisms and prevention of UV-induced melanoma", Photodermatol. Photoimmunol. Photomed, 34, pp.13~24 (2018)
89. Sun, X., "Ultraviolet radiation and melanomagenesis : from mechanism to immunotherapy", Front. Oncol, 10, pp.951~ (2020)
90. Nishiya, A. T., "Comparative aspects of canine melanoma", Vet. Sci, 3, pp.7~ (2016)
91. Simpson, R. M., "Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma", Pigment Cell Melanoma Res, 27, pp.37~47 (2014)
92. Deacon, D. C., "Molecular biomarkers for melanoma screening, diagnosis and prognosis : current state and future prospects", Front. Med, 8, pp.642380~ (2021)
93. Fonseca-Alves, C. E., "Current status of canine melanoma diagnosis and therapy : report from a colloquium on canine melanoma organized by ABROVET(Brazilian Association of Veterinary Oncology)", Front. Vet. Sci, 8, pp.707025~ (2021)
94. Shtivelman, E., "Pathways and therapeutic targets in melanoma", Oncotarget, 5, pp.1701~1752 (2014)
95. Hendricks, W. P. D., "Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis", PLoS Genet, 14, pp.e1007589~ (2018)
96. Prouteau, A., "Canine melanomas as models for human melanomas : clinical, histological, and genetic comparison", Genes, 10, pp.501~ (2019)
97. Wong, K., "Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma", Nat. Commun, 10, pp.353~ (2019)
98. Wei, B. R., "Synergistic targeted inhibition of MEK and dual PI3K", mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma, 2016, pp.29, 643~655
99. Hayward, N. K., "Whole-genome landscapes of major melanoma subtypes", Nature, 545, pp.175~180 (2017)
100. Fowles, J. S., "Comparative analysis of MAPK and PI3K", AKT pathway activation and inhibition in human and canine melanoma, 2015, pp.13, 288~304
101. Hartley, G., "Immune regulation of canine tumour and macrophage PD-L1expression", Vet. Comp. Oncol, 15, pp.534~549 (2017)
102. Maekawa, N., "PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma", NPJ Precis. Oncol, 5, pp.10~ (2021)
103. Stevenson, V. B., "PD-1, PD-L1, and PD-L2 gene expression and tumor infiltrating lymphocytes in canine melanoma", Vet. Pathol, 58, pp.692~698 (2021)
104. Maekawa, N., "Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy", Sci. Rep, 12, pp.9265~ (2022)
105. Jiang, M., "Lymphoma classification update : T-cell lymphomas, Hodgkin lymphomas, and histiocytic", dendritic cell neoplasms, 2017, pp.10, 239~249
106. Seelig, D. M., "The comparative diagnostic features of canine and human lymphoma", Vet. Sci, 3, pp.11~ (2016)
107. Ito, D., "Canine lymphoma as a comparative model for human non-Hodgkin lymphoma : recent progress and applications", Vet. Immunol. Immunopathol, 159, pp.192~201 (2014)
108. Dias, J. N. R., "Immunotherapeutic strategies for canine lymphoma : changing the odds against non-Hodgkin lymphoma", Front. Vet. Sci, 8, pp.621758~ (2021)
109. McDonald, J. T., "Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel", Oncotarget, 9, pp.22693~22702 (2018)
110. Marconato, L., "The dog as a possible animal model for human non-Hodgkin lymphoma : a review", Hematol. Oncol, 31, pp.1~9 (2013)
111. Ponce, F., "A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology", Vet. Pathol, 47, pp.414~433 (2010)
112. Harris, L. J., "Clinical features of canine nodal T-cell lymphomas classified as CD8+ or CD4-CD8-by flow cytometry", Vet. Comp. Oncol, 18, pp.416~427 (2020)
113. Richards, K. L., "Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL", Cancer Res, 73, pp.5029~5039 (2013)
114. Giannuzzi, D., "Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq", PLoS ONE, 14, pp.e0215154~ (2019)
115. Ferraresso, S., "DNA methylation profiling reveals common signatures of tumorigenesis and defines epigenetic prognostic subtypes of canine diffuse large B-cell lymphoma", Sci. Rep, 7, pp.11591~ (2017)
116. Frantz, A. M., "Molecular profiling reveals prognostically significant subtypes of canine lymphoma", Vet. Pathol, 50, pp.693~703 (2013)
117. Aresu, L., "New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease", Haematologica, 104, pp.e256~e259 (2019)
118. Avery, A. C., "The genetic and molecular basis for canine models of human leukemia and lymphoma", Front. Oncol, 10, pp.23~ (2020)
119. Breen, M., "Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans-man and his best friend share more than companionship", Chromosome Res, 16, pp.145~154 (2008)
120. Culver, S., "Molecular characterization of canine BCR-ABL-positive chronic myelomonocytic leukemia before and after chemotherapy", Vet. Clin. Pathol, 42, pp.314~322 (2013)
121. Figueiredo, J. F., "Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog", Vet. Clin. Pathol, 41, pp.362~368 (2012)
122. Perez, M. L., "Partial cytogenetic response with toceranib and prednisone treatment in a young dog with chronic monocytic leukemia", Anticancer Drugs, 24, pp.1098~1103 (2013)
123. Giantin, M., "Evaluation of tyrosine-kinase receptor c-KIT (c-KIT) mutations, mRNA and protein expression in canine leukemia: might c-KIT represent a therapeutic target?", Vet. Immunol. Immunopathol, 152, pp.325~332 (2013)

관련 논문AI추천